Peter Campochiaro, MD
Enriched profileGeorge S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience · Wilmer Eye Institute
Peter Campochiaro is George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at Wilmer Eye Institute. OpenAlex indexes 540 publications with 42,532 citations (h-index 113); ClinicalTrials.gov lists 21 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Ophthalmology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Peter A. Campochiaro, MD, is George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at Wilmer Eye Institute, Johns Hopkins University School of Medicine. The public record shows 540 publications with 42,532 citations (h-index 113), centered on Retinal Diseases and Treatments, Retinal Development and Disorders, Retinal and Macular Surgery. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 9 companies, 13 NIH-funded awards (1990–2026).
- Most recent indexed publication: 2026 · bioRxiv
- Top research focus: Retinal Diseases and Treatments
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 338.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- Oral N-acetylcysteine for Retinitis Pigmentosa
Sponsor: Johns Hopkins University
- Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
Sponsor: Johns Hopkins University
- A Natural History Study to Evaluate Functional and Anatomical Progression in Retinitis Pigmentosa
Sponsor: Johns Hopkins University
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20252 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
- Genentech, Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
85.8%Antineovascularisation agents85%Faricimab-svoa100%Part B, office-administered≥15 patientsCorticosteroid0.4%Prednisolone Acetate100%Part D<11 patientsCancer & immunology
13.5%Vascular Endothelial Growth Factor Inhibitor13.5%Aflibercept100%Part B, office-administered≥59 patientsMusculoskeletal
0.7%Cyclooxygenase Inhibitor0.7%Ketorolac Tromethamine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
13 NIH research awards on record, funded 1990–2026 per NIH RePORTER. The latest:
- Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseases
Johns Hopkins University
FY2026$436,695R01EY036027 - NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa
Johns Hopkins University
FY2026$344,858UG1EY033286 - Topical delivery of HIF-1 inhibitors for retinal and choroidal vascular diseases
Johns Hopkins University
FY2025$371,191R01EY036027
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab.
The British journal of ophthalmology
Clinical Trial2024 - Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes.
Science advances
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Ranibizumab for Macular Edema following Central Retinal Vein Occlusion1,152 citations2010
- 03
- 04
- 05Seven new loci associated with age-related macular degeneration804 citations2013
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/peter-campochiaro-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/peter-campochiaro-31ba2126
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Peter-Campochiaro
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/wilmer-eye-institute-johns-hopkins-medicine_congratulations-to-dr-peter-campochiaro-activity-6664162263596834817-Ue0-
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
peoplebehindthescience.com/dr-peter-campochiaro
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →peoplebehindthescience.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Director
Retina Research Laboratory (Campochiaro Laboratory), Wilmer Eye Institute, Johns Hopkins
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗ - Editorial Board Member
Progress in Retinal and Eye Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sciencedirect.com ↗ - Member
Macula Society
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →maculasociety.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →arvo.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
Secondary affiliations
appointments beyond the home institution- Faculty
Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →neuroscience.jhu.edu ↗ - Scientific Advisor
Applied Genetic Technologies Corporation (AGTC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗ - Scientific Advisor
Retina, Allegro Ophthalmics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- Eye on the Cure Podcast
Episode 67, Dr. Peter Campochiaro (Foundation Fighting Blindness, June 7 2024), discussing N-acetylcysteine (NAC) for retinitis pigmentosa
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fightingblindness.org ↗ - People Behind the Science Podcast
Episode 408, Dr. Peter Campochiaro: Bringing to Light the Mechanisms of Retinal Diseases and Developing New Treatments
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →peoplebehindthescience.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.